124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma

Cistaro, Angelina; Quartuccio, Natale; Caobelli, Federico; Piccardo, Arnoldo; Paratore, Rosario; Coppolino, Pietro; Sperandeo, Alessandro; Arnone, Gaspare; Ficola, Umberto

doi:10.5603/nmr.2015.0024

Cited by 54 publications

(38 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In comparison, limited diagnostic information can be obtained using planar scintigraphy with [ 131 I] m IBG which is also used in radiotherapy to treat neuroendocrine tumours [4]. In contrast, positron emission tomography (PET) with [ 124 I] m IBG [5, 6] is less widely used but has the potential to provide more detailed functional information concerning normal and diseased states of the neuroendocrine system.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Radiosynthesis of no-carrier-added meta-[124I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma

Green

Lowe

Kadirvel

et al. 2016

J Radioanal Nucl Chem

View full text Add to dashboard Cite

Meta-iodobenzylguanidine (mIBG) has been radiolabelled at the no-carrier-added level with [124I] for a proof of concept study to assess the diagnostic accuracy of [124I]mIBG PET/CT in detecting metastatic deposits in patients diagnosed with metastatic neuroblastoma. Radiolabelling of mIBG was achieved via the iododesilylation reaction between [124I]sodium iodide and meta-trimethylsilylbenzylguanidine. [124I]mIBG was produced in 62–70 % radioiodide incorporation yield from [124I]sodium iodide. The average amount of formulated [124I]mIBG was 359 MBq (range 344–389 MBq) with an average specific radioactivity of 4.1 TBq μmol−1 (range 1.8–5.9 TBq μmol−1) at end of synthesis.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Its high risk form is associated with one of the worst prognoses of all childhood malignancies [6]. In vivo imaging for the accurate staging and measurement of response to therapy is critical to the risk stratification of patients with neuroblastoma in order to offer the most individually tailored treatment possible.…”

Section: Introductionmentioning

confidence: 99%

Radiosynthesis of no-carrier-added meta-[124I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma

Green

Lowe

Kadirvel

et al. 2016

J Radioanal Nucl Chem

View full text Add to dashboard Cite

show abstract

“…Radiolabeled 124 I-MIBG, with a physical halflife of 4.2 d for 124 I decay, allows for multiple-day imaging and has been used for dosimetric estimates. Pretherapeutic imaging to estimate disease distribution and burden is possible with high sensitivity in both neuroblastoma and PHEO patients (48,49). Radiation dosimetry predicted from animal data was favorable, with mean effective doses ranging from 0.34 mSv/MBq for adults to 1.9-3.75 for children 1 y old or younger (135).…”

Section: Strategies For Improving Net Targeting and Dose Delivery Witmentioning

confidence: 92%

Norepinephrine Transporter as a Target for Imaging and Therapy

Pandit‐Taskar

Modak

2017

J Nucl Med

View full text Add to dashboard Cite

The norepinephrine transporter (NET) is essential for norepinephrine uptake at the synaptic terminals and adrenal chromaffin cells. In neuroendocrine tumors, NET can be targeted for imaging as well as therapy. One of the most widely used theranostic agents targeting NET is metaiodobenzylguanidine (MIBG), a guanethidine analog of norepinephrine. 123 I/ 131 I-MIBG theranostics have been applied in the clinical evaluation and management of neuroendocrine tumors, especially in neuroblastoma, paraganglioma, and pheochromocytoma. 123 I-MIBG imaging is a mainstay in the evaluation of neuroblastoma, and 131 I-MIBG has been used for the treatment of relapsed high-risk neuroblastoma for several years, however, the outcome remains suboptimal. 131 I-MIBG has essentially been only palliative in paraganglioma/pheochromocytoma patients. Various techniques of improving therapeutic outcomes, such as dosimetric estimations, high-dose therapies, multiple fractionated administration and combination therapy with radiation sensitizers, chemotherapy, and other radionuclide therapies, are being evaluated. PET tracers targeting NET appear promising and may be more convenient options for the imaging and assessment after treatment. Here, we present an overview of NET as a target for theranostics; review its current role in some neuroendocrine tumors, such as neuroblastoma, paraganglioma/ pheochromocytoma, and carcinoids; and discuss approaches to improving targeting and theranostic outcomes.

show abstract

“…Preliminary experience in two pediatric patients with an IV dose of 50 MBq and image acquisition done at 24 and 48 h showed promise [53]. Improved characteristics of current PET/CT scanners allow decreasing administered amount of radioactivity while maintaining adequate image quality [54], though it must be noted that radiation exposure is a secondary concern in these children with lifethreatening disease and considerable mutagenic therapy.…”

Section: Labelled Mibgmentioning

confidence: 98%

“…Improvement in sensitivity, lesion detection, increased precision to count individual lesions and better characterization of skull lesions are incremental benefits. Accurate determination of semiquantitative TMRR (Total 123 I-MIBG retention ratio), MIBG/Curie score and SIOPEN (International Society of Pediatric Oncology Europe Neuroblastoma Group) score during scan interpretation improves extent of disease evaluation and may help in deciding the appropriate next step in management i.e., choosing between medical and surgical treatment [50][51][52][53]. The scoring, typically done using 123 I-mIBG, will likely be improved with 124 I-mIBG PET; the longer half-life of 124 I also enables delayed images up to a week after administration.…”

Section: Labelled Mibgmentioning

confidence: 99%

The role of iodine-124 positron emission tomography in molecular imaging

Mahajan

Divgi

2016

Clin Transl Imaging

View full text Add to dashboard Cite

Radioactive iodine has been, in various forms, the mainstay of Nuclear Medicine. Iodine-123 is the most widely used iodine isotope for single photon imaging. Iodine-125 continues to be used in diverse applications from in vitro radioassay to in vivo estimation of various pathophysiologic correlates. Iodine-131 ( 131 I), useful for imaging as well as therapy, has contributed more than any other radionuclide to the growth and sustenance of Nuclear Medicine. Positron emission tomography (PET) is an indispensable tool in current clinical practice, spurred by the rapid and increasing availability of radiopharmaceuticals for in vivo imaging. Most clinical PET imaging utilizes fluorine-18; there is a need for positron emitters with longer half-lives, suitable for imaging larger molecules of interest. Iodine-124 ( 124 I) has approximately 23 % positron emission; its 4-day half-life lends itself to sequential imaging, and its dosimetry is comparable to iodine-131. Iodine can be easily attached to a variety of molecules without alteration of physico-chemical or biologic properties. PET with 124 I-labeled molecules enables longitudinal in vivo assessment of their distribution; such pharmacokinetic and biodistribution information has considerable utility in oncologic and non-oncologic applications. We will provide a clinical perspective on the physical and chemical characteristics of 124 I, as the iodide, as well as radiolabeled to a wide variety of molecules of interest.Radioiodination is accomplished based on the chemical and biologic nature of the ligand to be studied, and issues of relevance will be highlighted. We will conclude by describing the current and potential future clinical applications of 124 I-based tracers used for molecular imaging in diagnosis and therapy.

show abstract

124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma

Cited by 54 publications

References 18 publications

Radiosynthesis of no-carrier-added meta-[124I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma

Radiosynthesis of no-carrier-added meta-[124I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma

Norepinephrine Transporter as a Target for Imaging and Therapy

The role of iodine-124 positron emission tomography in molecular imaging

Contact Info

Product

Resources

About